Trevi Therapeutics, Inc. 8K

Trevi Therapeutics reported Q2 2026 financial results and announced significant clinical trial progress for Haduvio along with strengthened liquidity from an April 2026 equity offering.

On August 6, 2026, Trevi Therapeutics, Inc. reported its financial results for the quarter ended June 30, 2026 and provided business updates, highlighting the initiation of its Phase 3 OCEAN-1 trial for idiopathic pulmonary fibrosis-related chronic cough and Phase 2b LAKE trial for refractory chronic cough during the second quarter, plans to initiate the Phase 3 OCEAN-2 trial in the third quarter of 2026, an FDA meeting request for a non-IPF interstitial lung disease-related chronic cough program, and the completion of an April 2026 underwritten common stock offering that helped increase cash, cash equivalents and marketable securities to $318.9 million, extending the company’s projected cash runway into 2030 despite a second quarter 2026 net loss of $17.8 million.

Filing Facts

CIK

1563880

Ticker

TRVI

Form

8K

Source Type

fda

Accession

0001193125-26-337974

Alert Tier

6